DrugPatentWatch Database Preview

Liraglutide recombinant - Generic Drug Details

What are the generic sources for liraglutide recombinant and what is the scope of liraglutide recombinant freedom to operate?

Liraglutide recombinant is the generic ingredient in two branded drugs marketed by Novo Nordisk Inc and is included in two NDAs. There are twenty-one patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Liraglutide recombinant has two hundred and ninety-two patent family members in twenty-six countries.

There are seven drug master file entries for liraglutide recombinant. One supplier is listed for this compound.

Summary for liraglutide recombinant

International Patents:	292
US Patents:	21
Tradenames:	2
Applicants:	1
NDAs:	2
Drug Master File Entries:	7
Suppliers / Packagers:	1
Bulk Api Vendors:	2
Clinical Trials:	344
Patent Applications:	2
Formulation / Manufacturing:	see details
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for liraglutide recombinant
DailyMed Link:	liraglutide recombinant at DailyMed

Pharmacology for liraglutide recombinant

Drug Class	GLP-1 Receptor Agonist
Mechanism of Action	Glucagon-like Peptide-1 (GLP-1) Agonists

Medical Subject Heading (MeSH) Categories for liraglutide recombinant

Hypoglycemic Agents
Incretins

Synonyms for liraglutide recombinant

liraglutide [rDNA origin]
liraglutide [rNDA origin] injection
liraglutide rDNA origin
Saxenda
SCHEMBL2900303

US Patents and Regulatory Information for liraglutide recombinant

+ Get email alerts for changes to this table

Glossary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novo Nordisk Inc	SAXENDA	liraglutide recombinant	SOLUTION;SUBCUTANEOUS	206321-001	Dec 23, 2014		RX	Yes	Yes	➤ Sign Up	➤ Sign Up	Y			➤ Sign Up
Novo Nordisk Inc	VICTOZA	liraglutide recombinant	SOLUTION;SUBCUTANEOUS	022341-001	Jan 25, 2010		RX	Yes	Yes	➤ Sign Up	➤ Sign Up				➤ Sign Up
Novo Nordisk Inc	SAXENDA	liraglutide recombinant	SOLUTION;SUBCUTANEOUS	206321-001	Dec 23, 2014		RX	Yes	Yes	➤ Sign Up	➤ Sign Up	Y			➤ Sign Up
Novo Nordisk Inc	SAXENDA	liraglutide recombinant	SOLUTION;SUBCUTANEOUS	206321-001	Dec 23, 2014		RX	Yes	Yes	➤ Sign Up	➤ Sign Up	Y			➤ Sign Up
Novo Nordisk Inc	SAXENDA	liraglutide recombinant	SOLUTION;SUBCUTANEOUS	206321-001	Dec 23, 2014		RX	Yes	Yes	➤ Sign Up	➤ Sign Up	Y			➤ Sign Up
Novo Nordisk Inc	SAXENDA	liraglutide recombinant	SOLUTION;SUBCUTANEOUS	206321-001	Dec 23, 2014		RX	Yes	Yes	➤ Sign Up	➤ Sign Up	Y			➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration

Expired US Patents for liraglutide recombinant

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novo Nordisk Inc	SAXENDA	liraglutide recombinant	SOLUTION;SUBCUTANEOUS	206321-001	Dec 23, 2014	➤ Sign Up	➤ Sign Up
Novo Nordisk Inc	VICTOZA	liraglutide recombinant	SOLUTION;SUBCUTANEOUS	022341-001	Jan 25, 2010	➤ Sign Up	➤ Sign Up
Novo Nordisk Inc	VICTOZA	liraglutide recombinant	SOLUTION;SUBCUTANEOUS	022341-001	Jan 25, 2010	➤ Sign Up	➤ Sign Up
Novo Nordisk Inc	VICTOZA	liraglutide recombinant	SOLUTION;SUBCUTANEOUS	022341-001	Jan 25, 2010	➤ Sign Up	➤ Sign Up
Novo Nordisk Inc	SAXENDA	liraglutide recombinant	SOLUTION;SUBCUTANEOUS	206321-001	Dec 23, 2014	➤ Sign Up	➤ Sign Up
Novo Nordisk Inc	VICTOZA	liraglutide recombinant	SOLUTION;SUBCUTANEOUS	022341-001	Jan 25, 2010	➤ Sign Up	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration

International Patents for liraglutide recombinant

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Country	Document Number	Estimated Expiration
Portugal	944648	➤ Sign Up
Russian Federation	2007114761	➤ Sign Up
Japan	4643122	➤ Sign Up
Denmark	2109474	➤ Sign Up
European Patent Office	1056774	➤ Sign Up
Brazil	PI0606607	➤ Sign Up
Country	Document Number	Estimated Expiration

Supplementary Protection Certificates for liraglutide recombinant

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
90067-4	Sweden	➤ Sign Up	PRODUCT NAME: COMBINATION OF INSULIN DEGLUDEC AND LIRAGLUTIDE; REG. NO/DATE: EU/1/14/974 20140918
0944648/01	Switzerland	➤ Sign Up	PRODUCT NAME: LIRAGLUTID; REGISTRATION NO/DATE: SWISSMEDIC 59329 11.12.2009
C0054	France	➤ Sign Up	PRODUCT NAME: LIRAGLUTIDE; REGISTRATION NO/DATE IN FRANCE: EU/1/09/529/001 DU 20090630; REGISTRATION NO/DATE AT EEC: EU/1/09/529/001 DU 20090630
2014000114	Germany	➤ Sign Up	PRODUCT NAME: KOMBINATION VON INSULIN DEGLUDEC UND LIRAGLUTIDE; REGISTRATION NO/DATE: EU/1/14/947 20140918
C/GB09/058	United Kingdom	➤ Sign Up	PRODUCT NAME: LIRAGLUTIDE; REGISTERED: UK EU/1/09/529/001 20090630
00698	Netherlands	➤ Sign Up	PRODUCT NAME: INSULINE DEGLUDEC EN LIRAGLUTIDE; REGISTRATION NO/DATE: EU/1/14/94765041 2014120918
Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description